XOMA Provides Update on Gevokizumab – Analyst Blog

By | January 2, 2013

XOMA Corporation ( XOMA ) recently announced that it intends to include active non-infectious anterior scleritis in the gevokizumab proof-of-concept program. Non-infectious anterior

More:
XOMA Provides Update on Gevokizumab – Analyst Blog